Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19

作者：Mark Berry, Amanda M. Kong, Roger Paredes, Julie Paone, Rohan J. Shah, Rebecca Taylor, Essy Mozaffari, Rikisha Gupta, Robert Gottlieb, Lourdes Mateu, Mazin Abdelghany, Jason D. Goldman, Anand P. Chokkalingam · 发表于：Scientific Reports · 年份：2025 · DOI：10.1038/s41598-025-06052-3 · 被引用次数：4 · 研究领域：COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19、Infectious Encephalopathies and Encephalitis

Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospital chargemaster data linked to closed claims was queried for patients aged ≥ 12 years hospitalized for ≥ 2 days with COVID-19 between May 1, 2020, and September 30, 2021. Relative risk between remdesivir-exposed and unexposed patients was calculated for 16 individual Long COVID outcomes and a composite of any Long COVID outcome, occurring 90-270 days after hospital admission. Subgroup analyses occurred in immunocompromised patients. Regression models accounted for censoring, competing risks, and treatment assignment weights; statistical inferences were adjusted for multiple comparisons. Among 3,661,303 hospitalized patients, 52,006 with COVID-19 were included; 20,246 (38.9%) were immunocompromised. In the overall and immunocompromised populations, respectively, 33.0% and 29.5% received remdesivir; the composite of ≥ 1 Long COVID outcome occurred in 55.5% and 62.9%. Patients administered remdesivir experienced lower risk of any Long COVID outcome (risk ratio, 0.96; 95% CI 0.94-0.97; adjusted P < 0.001). Risk for several individual Long COVID outcomes was lower in those receiving remdesivir in the overall and immunocompromised populations. In conclusion, exposure to remdesivir was associated ...